TrialHaematologica2019

Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial.

Ruth Wester et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.